What is the brand name of dapagliflozin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Brand Name for Dapagliflozin

The brand name for dapagliflozin is Farxiga in the United States and Forxiga in the European Union. 1, 2, 3, 4

Regional Naming

  • United States: Farxiga® (manufactured by AstraZeneca) 1, 2, 3
  • European Union: Forxiga® (manufactured by AstraZeneca) 1, 4, 5

Both brand names refer to the same medication—dapagliflozin, an SGLT2 inhibitor—with identical formulations and indications. The naming difference is purely regional marketing convention by the manufacturer.

Clinical Context

Dapagliflozin is available as oral film-coated tablets in 5 mg and 10 mg strengths 2. The drug has multiple FDA-approved indications beyond its original diabetes indication, including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease 2, 3, 4.

References

Research

SGLT-2 Inhibitors: Focus on Dapagliflozin.

Cardiology in review, 2024

Research

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.